Cancer Center Clinical Studies

1 - 10 of 32

Phase 1 Trial of CUDC-907

This study involves taking a study drug called CUDC-907.  CUDC-907 is an oral drug that blocks certain proteins in tumor cells; these proteins may be important in the growth of some cancers. The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents.  This study will also look at the levels of CUDC-907 in the blood over time after a dose. 

Carfilzomib in ALL

CHOP, in collaboration with Onyx Therapeutics, Inc., is conducting a study for children and young adults up to 21 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT02303821". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.  

Chemotherapy-induced Nausea and Vomiting Control

For patients (and parents of patients) that have been diagnosed with, pediatric acute lymphoblastic leukemia (ALL), nausea and vomiting are among the most bothersome symptoms during chemotherapy treatment. The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.

Alpelisib in PIK3CA-related overgrowth syndrome

The purpose of this study is to find out if alpelisib (BYL719; the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease. 

ALRN-6924 in Pediatric Cancer

This study involves taking a study drug called ALRN-6924. ALRN-6924 is an investigational cancer treatment that activates p53, which suppresses the growth of tumors by blocking proteins in the cell called MDM2 and MDMX that inhibit p53 from doing its job. The overall goals of this study are to evaluate the side effects and benefits of ALRN-6924 in patients with relapsed or treatment refractory solid tumor or brain tumor, and to determine the best dose of ALRN-6924 for children and adolescents. This study will also look at how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924 in the blood over time after a dose. 

Abemaciclib For Solid Tumors

The purpose of this study is to determine the highest safe dose of abemaciclib in patients with relapsed or treatment refractory solid tumors given in combination with the chemotherapy drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide (Part B).

Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes). This is the first study using this drug in children under 12 years of age. Repotrectinib is administered in capsule form or liquid suspension.  

Selpercatinib in Solid or CNS tumors with RET-Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called Selpercatinib in children whose cancers have a specific genetic change (RET-fusion or RET-mutation). Selpercatinib has been FDA-approved for adults and pediatric patients 12 years of age or older for certain types of lung and thyroid cancers. Selpercatinib is administered in capsule form, liquid suspension, or may also be administered by a feeding tube for subjects who are unable to swallow. 

AAML1921; Bosutinib for Chronic Myeloid Leukemia

This study involves taking a study drug called bosutinib. The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML). 


Pages